Investment Rating - The report gives a "Buy" rating for the company, with a target price of HKD 1.80 per share, based on a 21x PE valuation for 2025 [52][123]. Core Insights - The company is positioned for long-term growth in the cardiovascular intervention field, with expected revenues of CNY 12.56 billion, CNY 16.87 billion, and CNY 20.76 billion for 2024, 2025, and 2026 respectively [52][123]. - The company has a strong pipeline of innovative products, including three major aortic products that are expected to be approved soon, enhancing its competitive edge [44][42]. - The company has demonstrated a robust international expansion, with overseas revenue reaching CNY 2.75 billion in 2023, a year-on-year increase of 36% [116][117]. Summary by Sections Company Overview - The company focuses on the development of innovative medical devices for cardiovascular interventions, with a strong patent portfolio and a significant market presence in over 120 countries [73][116]. - In 2023, the company achieved revenue of CNY 12.67 billion, a year-on-year increase of 15.5%, driven primarily by sales of congenital heart disease occluders and covered stents [98][51]. Product Lines - The company has three main product lines: structural heart disease, peripheral vascular disease, and electrophysiology, with structural heart disease contributing CNY 4.96 billion in revenue, accounting for 39.1% of total revenue [98][75]. - The peripheral vascular business generated CNY 7.07 billion, representing 55.8% of total revenue, with significant growth in aortic covered stents [98][75]. Market Dynamics - The report highlights the increasing demand for aortic interventions, with the domestic market for aortic stents expected to grow significantly due to rising awareness and the shift towards minimally invasive procedures [22][24]. - The company is well-positioned to capture market share in the aortic stent segment, with a competitive advantage due to its innovative product offerings and strong clinical data [30][42]. Financial Performance - The company reported a gross margin of 78.6% in 2023, which is competitive compared to industry peers, and anticipates higher profitability with the launch of new innovative products [11][12]. - The financial forecast indicates a decline in net profit for 2023, but a rebound is expected in subsequent years, with projected growth rates of 12%, 27%, and 25% for 2024, 2025, and 2026 respectively [52][123]. Innovation and R&D - The company has developed a revolutionary iron-based absorbable stent technology, which combines the support of metal stents with the absorbability of biodegradable materials, showing promising clinical results [14][48]. - The iron-based stent has completed a successful III phase clinical trial, demonstrating high safety and efficacy, which is expected to enhance its market potential [111][130].

Financial Performance - The company reported revenue of approximately RMB 652.8 million for the six months ended June 30, 2024, representing an increase of about 2.1% compared to RMB 639.5 million for the same period in 2023[10]. - Gross profit for the same period was RMB 515.4 million, also reflecting a 2.1% increase from RMB 504.8 million year-on-year[8]. - Operating profit decreased by 20.8% to RMB 202.0 million, down from RMB 255.2 million in the previous year[8]. - Net profit attributable to the company's owners was approximately RMB 205.6 million, a decrease of 6.6% from RMB 220.2 million in the prior year[10]. - The company's basic and diluted earnings per share were RMB 4.6 cents, down 6.1% from RMB 4.9 cents in the same period last year[8]. - The company reported a net income tax expense of RMB 22,837,000 for the six months ended June 30, 2024, compared to RMB 43,770,000 in 2023, indicating a decrease of approximately 47.8%[113]. - The company reported a total comprehensive income of RMB 220,164,000 for the period, compared to RMB 40,523,000 in the same period last year, reflecting a significant increase[100]. Asset and Liability Management - Non-current assets increased by 5.5% to RMB 2,600.9 million, compared to RMB 2,465.2 million as of December 31, 2023[8]. - Total assets rose by 2.6% to RMB 4,819.6 million, up from RMB 4,696.4 million at the end of 2023[8]. - The total current assets amounted to approximately RMB 2,218.6 million, a slight decrease from RMB 2,231.1 million as of December 31, 2023[29]. - The total current liabilities as of June 30, 2024, were approximately RMB 826.5 million, up from RMB 770.1 million as of December 31, 2023[29]. - The company’s total equity as of June 30, 2024, was RMB 3,256,427,000, up from RMB 3,243,328,000 at the end of June 2023[100]. Sales and Market Performance - The company’s domestic sales decreased by approximately 4.7%, while overseas sales increased by approximately 29.8% year-on-year[10]. - The company’s revenue from mainland China accounted for about 75.1% of total revenue, down from 80.4% in the same period last year[10]. - Revenue from the structural heart disease business was approximately RMB 271.2 million, an increase of about 11.2% from RMB 243.9 million in the same period of 2023[14]. - Revenue from the peripheral vascular business was approximately RMB 380.7 million, reflecting a 5.0% increase from RMB 362.7 million in the same period of 2023[14]. Expenses and Cost Management - Sales and distribution expenses increased by approximately 25.8% from RMB 119.2 million for the six months ended June 30, 2023, to RMB 150.0 million for the six months ended June 30, 2024[19]. - Administrative expenses rose by approximately 21.6% from RMB 59.7 million to RMB 72.6 million during the same period, primarily due to increased employee costs related to share-based payments[20]. - Research and development expenses increased by approximately 26.5% from RMB 110.6 million to RMB 139.9 million, with total R&D costs rising to RMB 204.2 million, a 26.1% increase[21]. Investment and Financing Activities - The company invested $20.0 million in Ally Bridge Group Global Life Science Capital Partners V, L.P., with a fair value of approximately RMB 192.3 million as of June 30, 2024, representing 4.0% of total assets[18]. - The company raised bank loans amounting to RMB 99,000,000 during the reporting period, which was not present in the previous year[100]. - The company incurred a loss of RMB 18,243,000 from fair value changes in mixed funds for the six months ended June 30, 2024, compared to a loss of RMB 296,000 in 2023[111]. Corporate Governance and Compliance - The company has adopted the corporate governance code as per the Hong Kong Stock Exchange and has complied with all provisions for the six months ending June 30, 2024, except for the deviation regarding the roles of the Chairman and CEO[49]. - The board consists of six directors, including two executive directors, one non-executive director, and three independent non-executive directors, ensuring at least one independent director has appropriate professional qualifications[50]. - The audit committee, composed of three independent non-executive directors, has reviewed the interim results for the six months ending June 30, 2024, confirming compliance with relevant accounting standards and regulations[52]. Share-Based Payments and Stock Options - The company recognized approximately RMB 40,626,000 in share-based payment expenses for the stock option plans during the six months ended June 30, 2024, compared to RMB 25,524,000 in the same period of 2023[149]. - The total number of shares that may be issued upon the exercise of options granted under the share option plan is capped at 462,929,240 shares, which does not exceed 10% of the issued share capital as of September 17, 2021[62]. - The company has a performance-based vesting schedule for stock options, with varying percentages based on performance targets[72]. Research and Development - The company submitted 80 patent applications and successfully obtained approval for 69 patents during the six months ended June 30, 2024, bringing the total effective patent applications to 2,198, with 1,008 approved[13]. - The company is currently in the clinical follow-up phase for the thoracoabdominal aortic stent graft system, which has completed a one-year clinical follow-up in China[14]. - New product research and development expenses amounted to RMB 64,302,000 for the six months ended June 30, 2024, compared to RMB 51,320,000 in 2023, marking an increase of about 25.3%[118].

Financial Performance - For the six months ended June 30, 2024, the revenue was approximately RMB 652.8 million, an increase of about 2.1% compared to RMB 639.5 million for the same period in 2023[2]. - The gross profit for the same period was approximately RMB 515.4 million, reflecting a growth of about 2.1% from RMB 504.8 million in the previous year[2]. - The net profit attributable to the owners of the company was approximately RMB 205.6 million, a decrease of about 6.6% from RMB 220.2 million in the same period of 2023, primarily due to increased employee costs and reduced foreign exchange gains[2]. - The operating profit for the six months was RMB 202.0 million, down from RMB 255.2 million in the same period last year[4]. - The company reported a basic and diluted earnings per share of RMB 4.6 cents, down from RMB 4.9 cents in the same period last year[4]. - The company reported a pre-tax profit of RMB 208,645 thousand for the six months ended June 30, 2024, down from RMB 256,421 thousand for the same period in 2023[11][12]. - The company’s net profit attributable to shareholders was approximately RMB 205.6 million, a decrease of about RMB 14.6 million or approximately 6.6% compared to RMB 220.2 million in the same period of 2023[39]. - The company’s net profit attributable to shareholders decreased by approximately 8.6% from RMB 255.5 million for the six months ended June 30, 2023, to approximately RMB 233.6 million for the six months ending June 30, 2024[58]. - Excluding non-recurring items, the net profit attributable to shareholders decreased from approximately RMB 220.2 million to approximately RMB 205.6 million, a decline of about 6.6%[58]. Revenue Breakdown - For the six months ended June 30, 2024, total external sales amounted to RMB 652,831 thousand, with structural heart disease business contributing RMB 271,250 thousand, peripheral vascular business RMB 380,725 thousand, and electrophysiology business RMB 856 thousand[11]. - Revenue from the structural heart disease business was approximately RMB 271.2 million, representing an increase of about 11.2% compared to RMB 243.9 million in the same period of 2023[44]. - Revenue from the peripheral vascular business was approximately RMB 380.7 million, an increase of about 5.0% compared to RMB 362.7 million in the same period of 2023[45]. - Revenue from the electrophysiology business significantly decreased by approximately 97.3%, contributing only RMB 0.9 million compared to RMB 32.9 million in the same period of 2023[46]. - Domestic sales decreased by approximately 4.7%, while overseas sales increased by approximately 29.8% compared to the same period in 2023, driven by the company's active overseas expansion and effective marketing strategies[39]. Assets and Liabilities - The total assets as of June 30, 2024, were RMB 2,600.9 million, compared to RMB 2,465.2 million as of December 31, 2023[5]. - The total liabilities for the operating segments as of June 30, 2024, were RMB 322,641 thousand, compared to RMB 317,411 thousand as of December 31, 2023[14]. - The company's cash and cash equivalents decreased to RMB 832.6 million from RMB 979.3 million as of December 31, 2023[5]. - Trade receivables as of June 30, 2024, total RMB 122,173,000, an increase of 16.2% from RMB 105,185,000 as of December 31, 2023[29]. - Other receivables and prepayments amount to RMB 505,394,000 as of June 30, 2024, up from RMB 463,041,000 as of December 31, 2023, reflecting an increase of 9.1%[30]. - Trade payables as of June 30, 2024, are RMB 94,313,000, a decrease of 24.0% from RMB 124,086,000 as of December 31, 2023[33]. - The current liabilities totaled approximately RMB 826.5 million as of June 30, 2024, compared to RMB 770.1 million as of December 31, 2023[61]. - The company's debt-to-asset ratio was approximately 2.9% as of June 30, 2024, compared to zero as of December 31, 2023[64]. Research and Development - The company’s research and development expenses for the six months ended June 30, 2024, totaled RMB 139,926 thousand, compared to RMB 110,607 thousand for the same period in 2023[11][12]. - Research and development expenses increased by approximately 26.5% from about RMB 110.6 million for the six months ended June 30, 2023, to about RMB 139.9 million for the six months ended June 30, 2024[53]. - The company submitted 80 patent applications and successfully obtained 69 patents during the six months ended June 30, 2024, bringing the total to 2,198 effective patent applications, with 1,008 patents granted as of June 30, 2024[42]. Strategic Initiatives - The company has received regulatory approvals for several innovative medical devices, including the DiAcuTM biopsy needle and HeartRTM occluder, enhancing its product portfolio and market competitiveness[41]. - The company is currently in the clinical trial phase for several products, including the X-ClipTM transcatheter mitral valve clip system, which is expected to expand its offerings in the cardiovascular market[41]. - The group aims to identify growth opportunities within the healthcare sector and seeks strategic partnerships to enhance its product line and expand its business scale[66]. - The group is focusing on upgrading its left atrial appendage occluder to meet the growing treatment demand, with expectations of increasing global market share[72]. - The group is optimistic about the market performance of its domestic pacemaker series due to significant unmet demand for pacemaker implantation in China[74]. - The company is actively seeking collaboration and investment opportunities with high-growth potential enterprises in the global healthcare sector[80]. Corporate Governance and Compliance - The company is committed to high standards of corporate governance to protect shareholder interests and enhance corporate value[82]. - The audit committee reviewed the interim results, confirming compliance with relevant accounting standards and regulations[84].

Employee Loans and Share Incentive Plan - LifeTech Scientific Corporation reported a total of RMB 282,537,000 in employee loans related to the 2019 Share Incentive Plan[1] - A total of 312,620,000 shares were vested to certain employees, with 81,675,000 shares already delivered as of September 29, 2020[1] Share Acquisition - As of December 31, 2023, employees acquired all remaining 230,945,000 shares at a purchase price of HKD 1.35 per share[2]

Summary of the Conference Call Company Overview - The conference call was hosted by Huazhong Securities in collaboration with a roadshow, focusing on the listed company, Xiantian Technology [1] Key Points and Arguments - The meeting featured insights from the company's leadership, specifically from General Manager An, who shared updates on the company's recent operational status [1] Additional Important Content - The call aimed to engage with investors and provide a platform for discussing the company's strategies and performance [1]

Summary of the Conference Call Company Involved - The conference call involved **Xiantian Technology**, a publicly listed company. Core Points and Arguments - The meeting was organized by **Huazhong Securities** and included a summer strategy session, indicating a focus on current market conditions and company performance [1]. - Company leadership, specifically **Mr. An**, shared insights regarding the recent operational status of Xiantian Technology, suggesting a proactive approach to investor communication [1]. Other Important Content - The event highlights the importance of direct engagement with investors, which may enhance transparency and trust in the company's operations [1].

Summary of Conference Call Notes Company and Industry - The company is focused on developing a biodegradable iron-zinc polylactic acid stent for the treatment of coronary heart disease [1] Core Points and Arguments - **Product Advantages**: - Simple operation process with lower operational costs [1] - Strong practicality, avoiding the drawbacks of permanent metal stents [1] - Excellent quality with good degradation speed and stability, with continuous improvements in clinical products [1] - **Current Clinical Status**: - Phase II clinical trials show a higher sample lesion rate but still yield good results [1] - Phase III clinical testing is complete, with follow-up required for 1-2 months [1] - Overall effectiveness is good, significantly better than competitors [1] - **European Clinical Collaboration**: - Ongoing discussions for collaboration with a European expert for clinical trials, which may enhance effectiveness and recognition [1] - Clinical testing process remains unpredictable [1] - **Product Deficiencies**: - Rapid corrosion rate of metal iron, with plans for future improvements [1] - Slow metabolic rate of iron and polylactic acid in the human body, though not a major concern [1] Additional Important Content - **Market Entry Timeline**: - CE application for the coronary stent submitted in May, with changes in European standards (MDD to MDR) causing delays [2] - Anticipation to obtain CE certification by the end of next year in China, requiring all clinical reports and data prior to submission [2] - Currently holds 50 technical patents in China and 24-25 in Europe [2] - **Replacement Rate of Biodegradable Stents**: - Achieving comparable effectiveness to permanent stents is considered a significant victory [3] - Permanent stents are prone to fatigue and fracture, leading to higher failure rates of target vessels [3] - Biodegradable stents perform better in secondary treatments, which is a concern for permanent stents [3] - **Commercialization in Overseas Markets**: - Seeking business development partnerships to aid international expansion, particularly in Japan [4] - Confident in the European market with ongoing clinical trials, which will facilitate CE certification [4] - No immediate plans for the U.S. market due to funding constraints for clinical testing [4] - **Current Objectives**: - Successfully complete European clinical tests and follow-ups to obtain CE certification [5] - Aim for commercialization and industrialization of the product [5] - Plan to apply for CE standards in South American and BRICS countries, which are easier to obtain [5]

Financial Performance - The company reported a revenue of approximately RMB 1,267.2 million for the year ended December 31, 2023, representing a 15.5% increase from RMB 1,097.3 million in 2022[7]. - Gross profit for the same period was approximately RMB 995.6 million, up 13.9% from RMB 873.9 million in the previous year[10]. - The net profit attributable to the company's owners decreased by 19.1% to RMB 263.2 million from RMB 325.3 million in 2022[7]. - Basic earnings per share fell to RMB 0.060 from RMB 0.077, a decline of 22.1%[7]. - Operating profit increased by approximately 2.0% to about RMB 383.3 million for the year ended December 31, 2023, from RMB 375.9 million in 2022[32]. - The company recorded a net profit attributable to owners of approximately RMB 263.2 million for the year ended December 31, 2023, down about 19.1% from RMB 325.3 million in 2022[38]. - The total comprehensive income for the year was RMB 510,066,000, down from RMB 516,664,000 in 2022[183]. - The company reported a net profit for 2023 decreased to RMB 107,490 thousand from RMB 318,739 thousand in 2022, indicating a decline of 66.3%[180]. Research and Development - The company experienced a significant increase in R&D expenses, impacting overall profitability[10]. - The company plans to continue increasing R&D investment and attracting talent to enhance its innovation capabilities[11]. - Research and development expenses increased by approximately 42.9% to about RMB 297.9 million for the year ended December 31, 2023, from RMB 208.5 million in 2022[31]. - The company has accelerated product development and innovation capabilities to maintain its leading position in the industry, with several products receiving regulatory certifications, including AcuMarkTM and EpioneTM systems[18]. - The company is actively expanding its product portfolio in the structural heart disease sector, with a diverse range of offerings including left atrial appendage occluders and third-generation congenital heart disease occluders[21]. - The company plans to increase R&D investment focusing on new materials and technologies to drive product innovation and category expansion[56]. Market and Sales - Domestic sales accounted for approximately 78.3% of total revenue in 2023, down from 81.6% in 2022, while overseas sales increased by 36.0%[16]. - The company's major overseas markets in 2023 were Asia (excluding mainland China) and Europe, contributing approximately 9.0% and 8.8% to total revenue, respectively[16]. - The company anticipates an upward trend in market demand for its products driven by aging population, urbanization, and increased health awareness[51]. - The global market for left atrial appendage occluders is expected to continue expanding due to a large population of atrial fibrillation patients[52]. - The company leads the domestic market share in the provision of advanced interventional medical devices for peripheral vascular diseases[53]. - The company is the first domestic manufacturer with a complete product range of implantable cardiac pacemakers meeting international standards, with optimistic market performance expected due to unmet demand in China[54]. Assets and Liabilities - Total assets increased to RMB 4,696.4 million in 2023 from RMB 3,690.1 million in 2022[8]. - The company’s total liabilities rose to RMB 1,372.4 million in 2023, compared to RMB 769.0 million in the previous year[8]. - As of December 31, 2023, the total current assets amounted to approximately RMB 2,231.1 million, an increase of about 59.6% from RMB 1,396.7 million as of December 31, 2022[40]. - The total current liabilities as of December 31, 2023, were approximately RMB 770.1 million, up from RMB 584.7 million as of December 31, 2022[40]. - The company's equity attributable to equity holders was approximately RMB 3,370.2 million as of December 31, 2023, compared to RMB 2,900.4 million as of December 31, 2022[43]. - The company has no bank borrowings as of December 31, 2023, resulting in a debt-to-equity ratio of zero[43]. Corporate Governance - The company has adopted corporate governance principles and confirmed compliance with the corporate governance code throughout the year ending December 31, 2023, except for a deviation regarding the dual role of the chairman and CEO[67]. - The board consists of two executive directors, one non-executive director, and three independent non-executive directors as of the report date[69]. - The company is committed to reviewing and enhancing its corporate governance practices to meet the rising expectations of shareholders and investors[67]. - The company has implemented a code of conduct for securities trading that meets or exceeds the standards set forth in the listing rules[68]. - The board has established clear guidelines for management reporting to the board, ensuring accountability and transparency in decision-making[74]. - The company has established a whistleblowing policy to encourage reporting of illegal or unethical behavior[95]. Shareholder Engagement - The annual general meeting provided shareholders the opportunity to engage directly with the board regarding company performance and operations[101]. - The company has maintained a high level of transparency in its communications with shareholders and investors[100]. - The board has reviewed the implementation and effectiveness of the shareholder communication policy for the year ending December 31, 2023[100]. Employee and Management - Total employee costs, including director remuneration, amounted to approximately RMB 3,798 million for the year ended December 31, 2023, up from RMB 3,365 million in 2022[55]. - The company has expanded its board with experienced professionals, enhancing its strategic planning and business management capabilities[59][60][62]. - The management team has a strong educational background, with degrees from prestigious institutions such as Tsinghua University and Fourth Military Medical University[59][61][62]. - The company is committed to creating environmentally friendly and sustainable business operations, investing in energy-saving technologies to reduce carbon emissions[57]. Audit and Compliance - The consolidated financial statements were audited by Deloitte, and no change in auditors has occurred in the past three years[171]. - The audit committee is responsible for recommending the appointment, reappointment, and removal of external auditors to the board[93]. - The company emphasizes effective risk management and internal control systems to safeguard assets and ensure compliance with laws and regulations[83]. - The board reviews the effectiveness of the risk management and internal control systems at least annually, ensuring they are adequate and effective[94]. Future Outlook - The company recognizes the opportunities in the medical device industry will outweigh the challenges in the future, driven by factors such as aging population and rising health awareness[13]. - The company plans to continue evaluating and exploring acquisition, partnership, alliance, and licensing opportunities globally in 2024 to enhance competitiveness in existing and newly selected markets[13].

Core Insights - The company, Xianjian Technology, reported a strong revenue growth of approximately 15.5% year-on-year, reaching around RMB 1,267.2 million for the year ending December 31, 2023, with overseas sales increasing significantly by about 36.0% [1][2] - The gross profit was approximately RMB 995.6 million, reflecting a stable gross margin of about 78.6%, while the net profit attributable to shareholders was around RMB 423.3 million, with a net profit margin of approximately 33.4% [1][2] - The company maintained a robust cash position with cash and cash equivalents amounting to approximately RMB 979.3 million, a year-on-year increase of about 17.5% [1] International Business Growth - The international business segment showed strong performance, with sales contributions from overseas markets rising to about 21.7% of total revenue, particularly driven by a 52.9% growth in the European market [1][2] - The company expanded its sales channels to nearly 120 countries and regions globally, enhancing its market penetration [1][2] Domestic Market Performance - The domestic market remains the foundation of the company's operations, contributing approximately 78.3% of total revenue with a year-on-year sales growth of about 10.8% [2] - The company’s structural heart disease products, including left atrial appendage occluders and congenital heart disease occluders, recorded a revenue increase of approximately 25.6% [2] Core Business Segments - The structural heart disease segment generated approximately RMB 495.7 million in sales, with left atrial appendage occluders growing by about 32.0% year-on-year [2] - The peripheral vascular business reported revenue of approximately RMB 707.1 million, a year-on-year increase of about 9.7%, with a notable growth in stent sales [3][4] - The electrophysiology segment achieved sales of approximately RMB 64.4 million, reflecting a growth of about 10.3% [4] Innovation and R&D - The company invested approximately RMB 297.9 million in R&D, marking a year-on-year increase of about 42.9%, to enhance its technological innovation capabilities [5] - Several innovative products received regulatory approvals, including AcuMark™ and Aegisy™ systems, which are expected to drive future growth [6] Strategic Developments - The subsidiary, Yuanxin Technology, completed a strategic financing round, significantly increasing its valuation by 173%, which will support the development of its iron-based bioabsorbable materials [7][8] - The company has submitted multiple products for regulatory approval in various markets, including CE certification in Europe and NMPA approval in China [6][8] Intellectual Property and Recognition - The company has submitted a total of 2,147 patent applications, with 942 patents granted, showcasing its commitment to innovation and intellectual property protection [8] - The company received several industry awards for its innovative products, highlighting its recognition in the medical device sector [8]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確性或完整性亦不發表任何聲明，並表 明不會就本公佈全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 LifeTech Scientific Corporation 先健科技公司 （在開曼群島註冊成立的有限公司） （股份代號：1302） 截至二零二三年十二月三十一日止年度的 年度業績公佈 | --- | --- | |-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | 財務摘 ...